French pharmaceutical firm Servier has announced a global licensing agreement with US-based Black Diamond Therapeutics (NASDAQ: BDTX) concerning BDTX-4933, a small molecule targeted therapy for solid tumors. The deal underscores a significant collaboration aimed at advancing the treatment landscape for multiple cancer indications.
Deal Structure and Financial Terms
Under the agreement, Servier will spearhead the development and worldwide commercialization of BDTX-4933 across various indications, including non-small cell lung cancer (NSCLC), with potential applications in other solid tumors. In return, Servier will pay Black Diamond an upfront fee of USD70 million and is committed to up to USD710 million in development and commercial sales milestone payments. Additionally, tiered royalties based on global net sales will be part of the financial arrangement.
Therapeutic Innovation and Development Stage
BDTX-4933 represents a novel therapeutic approach targeting RAS and RAF alterations in solid tumors and is currently in Phase I development. The first-in-human study, which includes dose escalation and expansion cohorts, is designed to evaluate the safety, tolerability, and antitumor activity of BDTX-4933 in adults with recurrent advanced or metastatic cancers harboring BRAF, CRAF, or NRAS mutations. This study will also help determine the preliminary recommended Phase 2 dose.-Fineline Info & Tech
Leave a Reply